References
- Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organization (CDMO). http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2017/Thermo-Fisher-Scientific-to-Acquire-Patheon-a-Leading-Contract-Development-and-Manufacturing-Organization-CDMO/default.aspx.
- DURECT and Sandoz Have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States. http://investors.durect.com/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=2270681.
- Doraiswamy A Meisner J Verity N . A new method for treating postoperative pain associated with laparoscopic surgery. Poster session presented at : 2016 Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting. Boston, MA, USA, 16–19 March 2016. www.durect.com/science-technologies/publications/posimir-saber-bupivacaine/.
- Senseonics and TypeZero Sign Development Agreement for Artificial Pancreas and Decision Support Systems. www.senseonics.com/investor-relations/news-releases/2017/05–11–2017–215934769.
- New Research Collaboration Between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds. http://ir.nektar.com/releasedetail.cfm?ReleaseID=1027335.
- Nektar Therapeutics . www.nektar.com/science/research-platform-hidden.
- Charych DH Hoch U Langowski JL et al. NKTR-214, an engineered cytokine with biased il2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res.22 (3), 680 –6 90 (2016).
- Exscientia Announces Eur 250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi. www.exscientia.co.uk/news.
- Sangamo Therapeutics and Pfizer Announce Collaboration for Hemophilia A Gene Therapy. http://investor.sangamo.com/press-releases/detail/359/sangamo-therapeutics-and-pfizer-announce-collaboration-for.
- Sangamo Receives Fast Track Designation from the FDA for SB-525 Investigational Hemophilia A Gene Therapy. http://investor.sangamo.com/press-releases/detail/363/sangamo-receives-fast-track-designation-from-the-fda-for.
- Heptares to Receive US$5 Million Milestone Payment from Teva. www.heptares.com/news/304/74/Heptares-to-Receive-US-5-Million-Milestone-Payment-from-Teva.html.
- Heptares Therapeutics . www.heptares.com.
- FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature. www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm.
- FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors. www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-adult-and-pediatr.
- CO.DON: Decisive Step Towards European Expansion. www.codon.de/news-overview/press-release/read-news/article/codon_entscheidender_meilenstein_schritt_auf_dem_weg_der_europaeischen_expansion.html?L=1&cHash=f8ddffbcdc15cccc7e2edee9b777375e.
- Summary of CHMP Opinion: Spherox. www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002736/WC500228068.pdf.
- Braeburn Pharmaceuticals and Camurus Announce Positive Top-Line Results from Long-Term Phase III Safety Study of CAM2038. www.prnewswire.com/news-releases/braeburn-pharmaceuticals-and-camurus-announce-positive-top-line-results-from-long-term-phase-3-safety-study-of-cam2038–300449203.html.
- Camurus . www.camurus.com/camurus.
- Ionis Pharmaceuticals Announces Phase III NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary End points. www.prnewswire.com/news-releases/ionis-pharmaceuticals-announces-phase-3-neuro-ttr-study-of-inotersen-ionis-ttr-rx-meets-both-primary-endpoints-300457281.html.
- Ionis Pharmaceutical . www.ionispharma.com/pipeline.
- ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes. www.prnewswire.com/news-releases/viacyte-receives-ind-allowance-from-fda-and-clearance-from-health-canada-to-commence-international-clinical-trial-of-pec-direct-cell-therapy-for-high-risk-type-1-diabetes-300461166.html.
- Egalet Announces Results of Arymo® ER Harm Reduction Modeling Analysis. http://egalet.investorroom.com/2017–05–18-Egalet-Announces-Results-of-ARYMO-R-ER-Harm-Reduction-Modeling-Analysis.
- Egalet Receives FDA Approval for ARYMO™ ER (Morphine Sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain. Press Release Egalet Corporation website. http://egalet.investorroom.com/news-releases?year=2017.
- Egalet Corporation . http://egalet.com.
- Key Patent Issues Covering Protagonist Therapeutics’ Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200. www.prnewswire.com/news-releases/key-patent-issues-covering-protagonist-therapeutics-oral-peptide-il-23-receptor-antagonists-including-the-development-candidate-ptg-200–300452029.html.
- Protagonist Therapeutics, Inc. US9624268 (2017).
- Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease. http://investors.protagonist-inc.com/phoenix.zhtml?c=254413&p=irol-newsArticle&ID=2277187.
- Ocugen Expands Global Patent Portfolio for OCU200. www.prnewswire.com/news-releases/ocugen-expands-global-patent-portfolio-for-ocu200–300453106.html.
- Ocugen . http://ocugen.com.